Figure 2
From: LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1
Effects of LSD and MDL100907 on cumulative motor activities in β-arrestin 2 mice. A description of the experimental design is provided in the legend for Fig. 1. The cumulative baseline results (0–30 min) are shown in Supplementary Table S2. Two-way ANOVAs failed to identify any significant effects for baseline locomotion, rearing, or stereotypy. (a) LSD-stimulated locomotor activities in WT and βArr2-KO subjects. A two-way ANOVA reported a significant treatment effect [F(5,96) = 18.578, p < 0.001] and a significant genotype by treatment interaction [F(5,96) = 5.273, p < 0.001]. (b) LSD-stimulated rearing activities in βArr2 animals. A two-way ANOVA observed a significant treatment effect [F(5,96) = 7.150, p < 0.001] and a significant genotype by treatment interaction [F(5,96) = 3.437, p = 0.007]. (c) LSD-stimulated stereotypical activities in βArr2 mice. A two-way ANOVA identified a significant treatment effect [F(5,96) = 4.242, p = 0.002]. N = 8–12 mice/group. ***p < 0.001, WT vs. KO; +++p < 0.001, LSD vs. designated groups within genotype; ^p < 0.05, 0.05 MDL + LSD vs. controls within genotype. Bonferroni corrected post-hoc tests for stereotypy for treatment effects: p < 0.05, LSD vs. vehicle and MDL controls; p < 0.01, LSD vs. 0.5 MDL + LSD.
